# Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1

> **NCT07486934** · PHASE3 · RECRUITING · sponsor: **Dyne Therapeutics** · enrollment: 150 (estimated)

## Conditions studied

- Myotonic Dystrophy Type 1 (DM1)
- DM1
- Myotonic Dystrophy
- Steinert Disease
- Steinert

## Interventions

- **DRUG:** zeleciment basivarsen (DYNE-101)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07486934
- **Lead sponsor:** Dyne Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2028-07
- **Final completion:** 2029-01
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07486934

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07486934, "Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07486934. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*